May Health Secures $25M to Revolutionize PCOS Treatment
May 14, 2024, 9:48 am
May Health, a Paris-based medical device company, recently closed a $25M Series B funding round led by Bpifrance and Trill Impact Ventures. The funding will propel the development of their innovative Ovarian Rebalancing™ therapy, aimed at addressing PCOS-related infertility.
May Health, under the leadership of CEO Anne Morrissey, is on a mission to provide new hope for women struggling with PCOS. Their groundbreaking approach to fertility treatment has the potential to revolutionize the way we think about PCOS-related infertility.
With the support of investors like Sofinnova Partners, Avestria Ventures, and Kidron Capital Assets LP, May Health is poised to make a significant impact in the field of women's health. The addition of Nina Rawal and Jean-Francois Morin to the company's Board of Directors further solidifies their commitment to driving innovation in the treatment of PCOS.
The upcoming REBALANCE Study will be a pivotal moment for May Health, as they seek to demonstrate the safety and efficacy of their Ovarian Rebalancing™ therapy. This study has the potential to change the lives of millions of women worldwide who are affected by PCOS.
Anne Morrissey expressed her gratitude to the investors and supporters who have shown confidence in May Health's vision. She emphasized the company's dedication to becoming a global leader in women's health and PCOS-related infertility, highlighting the positive results of their previous clinical studies.
May Health's focus on addressing the physical, emotional, and mental health challenges faced by women with PCOS sets them apart as a company with a deep understanding of the needs of their target demographic. By providing a safe and straightforward treatment option for activating natural ovulation, May Health is paving the way for a brighter future for women with PCOS.
The impact of PCOS goes beyond fertility issues, affecting women's overall health and well-being. May Health's commitment to contributing to the UN Sustainable Development Goals underscores their dedication to improving the lives of women globally.
As May Health continues to push the boundaries of innovation in women's health, their recent funding round marks a significant milestone in their journey towards transforming the landscape of PCOS treatment. With a team of experienced professionals and a clear vision for the future, May Health is poised to make a lasting impact on the lives of women around the world.
May Health, under the leadership of CEO Anne Morrissey, is on a mission to provide new hope for women struggling with PCOS. Their groundbreaking approach to fertility treatment has the potential to revolutionize the way we think about PCOS-related infertility.
With the support of investors like Sofinnova Partners, Avestria Ventures, and Kidron Capital Assets LP, May Health is poised to make a significant impact in the field of women's health. The addition of Nina Rawal and Jean-Francois Morin to the company's Board of Directors further solidifies their commitment to driving innovation in the treatment of PCOS.
The upcoming REBALANCE Study will be a pivotal moment for May Health, as they seek to demonstrate the safety and efficacy of their Ovarian Rebalancing™ therapy. This study has the potential to change the lives of millions of women worldwide who are affected by PCOS.
Anne Morrissey expressed her gratitude to the investors and supporters who have shown confidence in May Health's vision. She emphasized the company's dedication to becoming a global leader in women's health and PCOS-related infertility, highlighting the positive results of their previous clinical studies.
May Health's focus on addressing the physical, emotional, and mental health challenges faced by women with PCOS sets them apart as a company with a deep understanding of the needs of their target demographic. By providing a safe and straightforward treatment option for activating natural ovulation, May Health is paving the way for a brighter future for women with PCOS.
The impact of PCOS goes beyond fertility issues, affecting women's overall health and well-being. May Health's commitment to contributing to the UN Sustainable Development Goals underscores their dedication to improving the lives of women globally.
As May Health continues to push the boundaries of innovation in women's health, their recent funding round marks a significant milestone in their journey towards transforming the landscape of PCOS treatment. With a team of experienced professionals and a clear vision for the future, May Health is poised to make a lasting impact on the lives of women around the world.